Overview

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

Status:
NOT_YET_RECRUITING
Trial end date:
2030-12-31
Target enrollment:
Participant gender:
Summary
A Randomized, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Treatments:
6-pyruvoyltetrahydropterin synthase
tislelizumab